Goldman Sachs Group Inc Cytek Biosciences, Inc. Transaction History
Goldman Sachs Group Inc
- $780 Billion
- Q3 2025
A detailed history of Goldman Sachs Group Inc transactions in Cytek Biosciences, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,737,309 shares of CTKB stock, worth $9.56 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,737,309
Previous 1,016,557
70.9%
Holding current value
$9.56 Million
Previous $3.46 Million
74.42%
% of portfolio
0.0%
Previous 0.0%
Shares
23 transactions
Others Institutions Holding CTKB
# of Institutions
150Shares Held
72.8MCall Options Held
0Put Options Held
0-
Black Rock Inc. New York, NY17.1MShares$93.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.93MShares$38.1 Million0.0% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E96.66MShares$36.6 Million0.69% of portfolio
-
Brown Capital Management LLC Baltimore, MD4.96MShares$27.3 Million0.74% of portfolio
-
State Street Corp Boston, MA4.08MShares$22.5 Million0.0% of portfolio
About Cytek Biosciences, Inc.
- Ticker CTKB
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 134,627,008
- Market Cap $740M
- Description
- Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers ...